Ayako Nagayama Kenji Ashida Miki Watanabe Kanoko Moritaka Aya Sonezaki Yoichiro Kitajima Hirokazu Takahashi Satoko Yoshinobu Shimpei Iwata Junichi Yasuda Nao Hasuzawa Shuichi Ozono Seiichi Motomura Masatoshi Nomura
10.3389/fendo.2021.690996
Front Endocrinol (Lausanne)
2021 May 31;12:690996.
sglt2 inhibitor diabetes mellitus hypertriglyceridemia lipodystrophy metreleptin
CC BY
https://pubmed.ncbi.nlm.nih.gov/34135866/
Benzhydryl Compounds / therapeutic use Bone Marrow Transplantation / adverse effects Glucosides / therapeutic use Leptin / analogs & derivatives Lipodystrophy / drug therapy Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
Benzhydryl Compounds / therapeutic use Bone Marrow Transplantation / adverse effects Glucosides / therapeutic use Leptin / analogs & derivatives Lipodystrophy / drug therapy Sodium-Glucose Transporter 2 Inhibitors / therapeutic use Case Reports Drug Therapy, Combination Female Humans Hypoglycemic Agents / therapeutic use Leptin / therapeutic use Lipodystrophy / etiology Pioglitazone / therapeutic use Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy Treatment Outcome Young Adult Benzhydryl Compounds Glucosides Hypoglycemic Agents Leptin Sodium-Glucose Transporter 2 Inhibitors empagliflozin metreleptin Pioglitazone Lipodystrophy, Partial, Acquired
PMC8201990
34135866
Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy
2021